Saturday 17 October 2026
Export LKFT’s income statement to Excel — free account
Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
29.90
0.03
−0.10%
Follow LKFT
| Jun '26 | Mar '26 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | — | — |
+8 more TTM periods Free account |
| 0.00% | (0.55%) | 0.00% | 0.00% | ||
| 0.00% | (0.45%) | 0.00% | 0.00% | ||
ROIC |
0.00% | (49.18%) | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (0.54%) | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 81.84 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (8.09) | 0.00 | 0.00 | |
Free Cash Flow |
(524.53) | (532.79) | (808.33) | (689.94) | |
Capital Expenditures |
(16.58) | (23.16) | (108.93) | (165.54) | |
| Other line items | |||||
Cash ROIC |
(8.19%) | (7.29%) | (12.58%) | (10.55%) | |
Accounts Receivable Turnover |
0.00 | 3.54 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.24 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.62 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 1,415.08 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 261.44 | 0.00 | 0.00 | |
Tax Rate |
— | (0.03) | — | — | |
Research and Development Expense of Revenue |
— | 146.51% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 65.79% | — | — | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Interest Coverage |
— | (70.87) | — | — | |
Operating CF/Net income |
0.00 | 26.52 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
— | 4.28 | — | — | |
Operating CF per Share |
0.00 | (7.74) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.35) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.08 | 0.00 | 0.00 |
Columns are period end dates